Last reviewed · How we verify

XR-tacrolimus QD + MMF BID then MMF QD

University Hospital, Limoges · FDA-approved active Small molecule

XR-tacrolimus QD + MMF BID then MMF QD is a Calcineurin inhibitor + Antimetabolite immunosuppressant combination Small molecule drug developed by University Hospital, Limoges. It is currently FDA-approved for Prevention of organ transplant rejection (renal, cardiac, hepatic transplantation).

This combination regimen suppresses T-cell activation and proliferation to prevent organ transplant rejection.

This combination regimen suppresses T-cell activation and proliferation to prevent organ transplant rejection. Used for Prevention of organ transplant rejection (renal, cardiac, hepatic transplantation).

At a glance

Generic nameXR-tacrolimus QD + MMF BID then MMF QD
SponsorUniversity Hospital, Limoges
Drug classCalcineurin inhibitor + Antimetabolite immunosuppressant combination
TargetCalcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)
ModalitySmall molecule
Therapeutic areaImmunology / Transplantation
PhaseFDA-approved

Mechanism of action

XR-tacrolimus is an extended-release calcineurin inhibitor that blocks T-cell activation by inhibiting calcineurin-dependent cytokine production. Mycophenolate mofetil (MMF) is an inosine monophosphate dehydrogenase inhibitor that selectively suppresses lymphocyte proliferation. Together, they provide dual immunosuppression for post-transplant maintenance therapy, with MMF dosing reduced over time as tacrolimus levels stabilize.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about XR-tacrolimus QD + MMF BID then MMF QD

What is XR-tacrolimus QD + MMF BID then MMF QD?

XR-tacrolimus QD + MMF BID then MMF QD is a Calcineurin inhibitor + Antimetabolite immunosuppressant combination drug developed by University Hospital, Limoges, indicated for Prevention of organ transplant rejection (renal, cardiac, hepatic transplantation).

How does XR-tacrolimus QD + MMF BID then MMF QD work?

This combination regimen suppresses T-cell activation and proliferation to prevent organ transplant rejection.

What is XR-tacrolimus QD + MMF BID then MMF QD used for?

XR-tacrolimus QD + MMF BID then MMF QD is indicated for Prevention of organ transplant rejection (renal, cardiac, hepatic transplantation).

Who makes XR-tacrolimus QD + MMF BID then MMF QD?

XR-tacrolimus QD + MMF BID then MMF QD is developed and marketed by University Hospital, Limoges (see full University Hospital, Limoges pipeline at /company/university-hospital-limoges).

What drug class is XR-tacrolimus QD + MMF BID then MMF QD in?

XR-tacrolimus QD + MMF BID then MMF QD belongs to the Calcineurin inhibitor + Antimetabolite immunosuppressant combination class. See all Calcineurin inhibitor + Antimetabolite immunosuppressant combination drugs at /class/calcineurin-inhibitor-antimetabolite-immunosuppressant-combination.

What development phase is XR-tacrolimus QD + MMF BID then MMF QD in?

XR-tacrolimus QD + MMF BID then MMF QD is FDA-approved (marketed).

What are the side effects of XR-tacrolimus QD + MMF BID then MMF QD?

Common side effects of XR-tacrolimus QD + MMF BID then MMF QD include Nephrotoxicity, Neurotoxicity (tremor, headache), Hyperglycemia, Hypertension, Gastrointestinal disturbance (diarrhea, nausea), Infections.

What does XR-tacrolimus QD + MMF BID then MMF QD target?

XR-tacrolimus QD + MMF BID then MMF QD targets Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil) and is a Calcineurin inhibitor + Antimetabolite immunosuppressant combination.

Related